NXL
Nexalin Technology, Inc.
NXL offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
UNH
UnitedHealth Group Incorporated
UNH has the edge over NXL overall, supported by lower modeled downside and stronger valuation.
NXL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
NXL's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
NXL PE Valuation
NXL has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
NXL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| High |
Analysts expect NXL's losses to shrink, with revenue growing.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
NXL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$13.63 | +$6.47 |
| Q2 2026 | -$14.10 | +$9.00 |
| Q1 2026 | -$13.80 | +$11.40 |
| Q4 2025 | -$15.00 | +$9.90 |
| Q3 2025 | -$20.10 | -$0.68 |
| Q2 2025 | -$23.10 | -$1.28 |
| Q1 2025 | -$25.20 | -$5.18 |
| Q4 2024 | -$24.90 | -$6.00 |
NXL is still losing money, but far less than before: $13.63 per share over the past year, against $34.20 at its worst in late 2021.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over NXL on earnings quality, reporting a profit while its opponent remains loss making.
NXL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $78.3K | +331% |
| Q2 2026 | $12.2K | -83% |
| Q1 2026 | $15K | -64% |
| Q4 2025 | $171.9K | +532% |
| Q3 2025 | $18.1K | -50% |
| Q2 2025 | $70.6K | +163% |
| Q1 2025 | $41K | -48% |
| Q4 2024 | $27.2K | +32% |
NXL's revenue is recovering but still below its 2022 peak: $78,301 last quarter, up 331% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -3332% | +9592 points |
| Q2 2026 | -18480% | -16184 points |
| Q1 2026 | -14180% | -9276 points |
| Q4 2025 | -1404% | +9176 points |
| Q3 2025 | -12924% | -5962 points |
| Q2 2025 | -2296% | +2536 points |
| Q1 2025 | -4904% | -3539 points |
| Q4 2024 | -10579% | -2669 points |
NXL's operating margin was −3332% last quarter, up 9592 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over NXL on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over NXL on profitability, with a higher operating margin.
NXL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.6M | -$121.5K |
| Q2 2026 | -$1.8M | -$884.5K |
| Q1 2026 | -$1.7M | -$286.8K |
| Q4 2025 | -$1.1M | -$13.5K |
| Q3 2025 | -$1.5M | -$666K |
| Q2 2025 | -$917.2K | +$329.3K |
| Q1 2025 | -$1.4M | -$662.9K |
| Q4 2024 | -$1.1M | -$130.4K |
NXL has burned cash in almost every quarter: −$6M over the past year, against −$5M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over NXL on cash generation, producing positive trailing cash flow while its opponent burns cash.
NXL Net Leverage
NXL's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
NXL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.1 | Oversold |
| Stochastic | 1.3 | Oversold |
NXL's weekly RSI is 29 (oversold) and its Stochastic is 1 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
NXL PE vs Healthcare Sector
NXL has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
NXL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.81 | 47% below |
| 20 week MA | $6.97 | 79% below |
| 50 week MA | $12.1 | 88% below |
| 100 week MA | $31.0 | 95% below |
| 200 week MA | $31.2 | 95% below |
NXL is in a downtrend: it's below all five of its weekly moving averages, and 95% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over NXL on trend strength, trading above more of its moving averages.
NXL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $67.5 | $23.4 | -65% |
| 2023 | $23.4 | $12.1 | -48% |
| 2024 | $12.1 | $88.5 | +629% |
| 2025 | $88.5 | $18.9 | -79% |
| 2026 YTD | $18.9 | $1.49 | -92% |
NXL's yearly returns have swung widely, from +629% in 2024 to −79% in 2025. It's down 92% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over NXL on returns for 2026, with the stronger performance.